menstrual blood stem cell therapy for covid-19

Phase 1

• Conditions: severe covid-19 patients.; COVID-19, virus identified; U07.1

• Registration Number: IRCT20180619040147N6
• Lead Sponsor: Iranian academic center for education culture and research

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 April 2021

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Aged 40-65 years
Voluntarily participate in this clinical trial and sign off informed consent form
Chest imaging confirm COVID-19 featured lesions in the lung
The SARS-CoV-2 nucleic acid test was positive
Diagnosed with severe pneumonia of COVID-19: respiratory distress, Respiratory rate (RR) = 30 times/min; resting oxygen saturation of 90% or less; arterial pressure of oxygen/the fraction of inspired oxygen= 300 mmHg; pulmonary imaging of focus within 24-48 hours > 50% progression

Exclusion Criteria

History of drug reactions or allergies
Pneumonia caused by bacteria, Mycoplasma, Chlamydia, Legionella, fungi, or other viruses
Airway obstruction due to lung cancer or unknown factors
Carcinoid syndrome
History of epilepsy and long-term use of anticonvulsant drugs during the last 3 years
History of long-term use of immunosuppressive drugs
History of chronic respiratory illness that requires long-term oxygen therapy
The patient is on blood or peritoneal dialysis
Creatinine clearance <15 ml / min
Moderate to severe liver disease (Child-Pugh score> 12)
History of deep vein thrombosis (DVT) or pulmonary embolism over the past 3 years
Being under ECMO or high-frequency oscillatory ventilation support
Diagnostic of HIV, hepatitis B, and syphilis
Pregnant or lactating women
Lack of consciousness and inability to provide informed consent by the patient

Study & Design

• Study Type: interventional
• Study Design: Not specified